Treatment of the antiphospholipid antibody syndrome: progress in the last five years?
The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.
Petri
M
M
Johns Hopkins University School of Medicine, 1830 E. Monument Street, Suite 7500, Baltimore, MD 21205, USA. MPETRI@welchlink.welch.jhu.edu
D000022:Abortion, Spontaneous / Q000188:drug therapy / Q000209:etiology; D016736:Antiphospholipid Syndrome / Q000145:classification / Q000150:complications / Q000628:therapy*; D001241:Aspirin / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007275:Injections, Intravenous; D010956:Plasmapheresis; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014859:Warfarin / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D006493:Heparin; D001241:Aspirin